173 related articles for article (PubMed ID: 21249357)
1. Pre-operative serum C-reactive protein as independent prognostic factor for survival but not infection in patients with high-grade osteosarcoma.
Funovics PT; Edelhauser G; Funovics MA; Laux C; Berzaczy D; Kubista B; Kotz RI; Dominkus M
Int Orthop; 2011 Oct; 35(10):1529-36. PubMed ID: 21249357
[TBL] [Abstract][Full Text] [Related]
2. Post operative infection and increased survival in osteosarcoma patients: are they associated?
Jeys LM; Grimer RJ; Carter SR; Tillman RM; Abudu A
Ann Surg Oncol; 2007 Oct; 14(10):2887-95. PubMed ID: 17653803
[TBL] [Abstract][Full Text] [Related]
3. Role of routine blood tests for predicting clinical outcomes in osteosarcoma patients.
Jettoo P; Tan G; Gerrand CH; Rankin KS
J Orthop Surg (Hong Kong); 2019; 27(2):2309499019838293. PubMed ID: 30909848
[TBL] [Abstract][Full Text] [Related]
4. Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma.
Tsuda Y; Tsoi K; Parry MC; Stevenson JD; Fujiwara T; Sumathi V; Jeys LM
Bone Joint J; 2020 Jun; 102-B(6):795-803. PubMed ID: 32475245
[TBL] [Abstract][Full Text] [Related]
5. Serum C-reactive protein and overall survival of patients with osteosarcoma.
Li X; Tian F; Wang F; Li Y
Tumour Biol; 2015 Jul; 36(7):5663-6. PubMed ID: 25986475
[TBL] [Abstract][Full Text] [Related]
6. Plasma proteome predicts chemotherapy response in osteosarcoma patients.
Li Y; Dang TA; Shen J; Hicks J; Chintagumpala M; Lau CC; Man TK
Oncol Rep; 2011 Feb; 25(2):303-14. PubMed ID: 21165584
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of the serum level of C-reactive protein for the survival of patients with a primary sarcoma of bone.
Nakamura T; Grimer RJ; Gaston CL; Watanuki M; Sudo A; Jeys L
Bone Joint J; 2013 Mar; 95-B(3):411-8. PubMed ID: 23450030
[TBL] [Abstract][Full Text] [Related]
8. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup.
Hauben EI; Weeden S; Pringle J; Van Marck EA; Hogendoorn PC
Eur J Cancer; 2002 Jun; 38(9):1218-25. PubMed ID: 12044509
[TBL] [Abstract][Full Text] [Related]
9. High serum alkaline phosphatase cooperating with MMP-9 predicts metastasis and poor prognosis in patients with primary osteosarcoma in Southern China.
Han J; Yong B; Luo C; Tan P; Peng T; Shen J
World J Surg Oncol; 2012 Feb; 10():37. PubMed ID: 22333159
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study.
Tabone MD; Brugières L; Piperno-Neumann S; Selva MA; Marec-Bérard P; Pacquement H; Lervat C; Corradini N; Gentet JC; Couderc R; Chevance A; Mahier-Ait Oukhatar C; Entz-Werle N; Blay JY; Le Deley MC
BMC Cancer; 2017 Jun; 17(1):419. PubMed ID: 28619014
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of long non-coding RNA TUG1 correlates with poor prognosis and disease status in osteosarcoma.
Ma B; Li M; Zhang L; Huang M; Lei JB; Fu GH; Liu CX; Lai QW; Chen QQ; Wang YL
Tumour Biol; 2016 Apr; 37(4):4445-55. PubMed ID: 26499949
[TBL] [Abstract][Full Text] [Related]
12. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
[TBL] [Abstract][Full Text] [Related]
13. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
Bajpai J; Chandrasekharan A; Talreja V; Simha V; Chandrakanth MV; Rekhi B; Khurana S; Khan A; Vora T; Ghosh J; Banavali SD; Gupta S
Eur J Cancer; 2017 Nov; 85():49-58. PubMed ID: 28888849
[TBL] [Abstract][Full Text] [Related]
14. Pre-treatment serum lactate dehydrogenase level is an important prognostic factor in high-grade extremity osteosarcoma.
González-Billalabeitia E; Hitt R; Fernández J; Conde E; Martínez-Tello F; Enríquez de Salamanca R; Cortés-Funes H
Clin Transl Oncol; 2009 Jul; 11(7):479-83. PubMed ID: 19574207
[TBL] [Abstract][Full Text] [Related]
15. The level of vascular endothelial growth factor as a predictor of a poor prognosis in osteosarcoma.
Kaya M; Wada T; Nagoya S; Sasaki M; Matsumura T; Yamashita T
J Bone Joint Surg Br; 2009 Jun; 91(6):784-8. PubMed ID: 19483233
[TBL] [Abstract][Full Text] [Related]
16. Circulating miR-148a is a significant diagnostic and prognostic biomarker for patients with osteosarcoma.
Ma W; Zhang X; Chai J; Chen P; Ren P; Gong M
Tumour Biol; 2014 Dec; 35(12):12467-72. PubMed ID: 25185654
[TBL] [Abstract][Full Text] [Related]
17. C-reactive protein as a prognostic factor in patients with chordoma of lumbar spine and sacrum--a single center pilot study.
Hobusch GM; Bodner F; Walzer S; Marculescu R; Funovics PT; Sulzbacher I; Windhager R; Panotopoulos J
World J Surg Oncol; 2016 Apr; 14():111. PubMed ID: 27091202
[TBL] [Abstract][Full Text] [Related]
18. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
[TBL] [Abstract][Full Text] [Related]
19. Histologic Response and Toxicity following Interval-Compressed Four-Drug Therapy Given Preoperatively in Children and Young Adults with Osteosarcoma: A Retrospective Study.
Kang JM; Ju HY; Joo J; Sung JY; Park SY; Kim JH; Kang HG; Kwon M; Park M; Park HJ; Park BK
Oncology; 2020; 98(2):81-90. PubMed ID: 31509843
[TBL] [Abstract][Full Text] [Related]
20. Combined pre-operative chemotherapy with intra-arterial cisplatin and continuous intravenous adriamycin for high grade osteosarcoma.
Rha SY; Chung HC; Gong SJ; Shim KY; Ahn JB; Yang WI; Shin KH; Yoo NC; Kim JH; Roh JK; Lee CI; Kim BS
Oncol Rep; 1999; 6(3):631-7. PubMed ID: 10203605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
